Business
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS
About this update from Tyra Biosciences, Inc.
[{"type":"text","content":"-Collaboration aims to raise awareness of UTUC and the need for continued innovation for patients living with this rare and difficult-to-treat cancer-CARLSBAD, Calif., May 21, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the establishment of Upper Tract Urothelial Cancer (UTUC) Awareness Day, in collaboration with the Bladder Cancer Advocacy Network (BCAN).UTUC is a rare cancer affecting the lining of the kidneys and ureters, with a high prevalence of activating FGFR3 alterations. Standard treatment approaches frequently involve endoscopic tumor ablation or, in more advanced cases, surgical removal of the kidney and ureter (nephroureterectomy), which can lead to long-term health complications. There remains a significant unmet need for an effective, kidney-sparing treatment option. Currently, there is no well-established systemic standard of care for patients with UTUC.Through this collaboration, TYRA and BCAN aim to increase awareness of the disease, amplify the patient experience, and highlight the importance of continued research and innovation for people living with UTUC.\"Patients diagnosed with UTUC often describe feeling isolated, overwhelmed, and uncertain about where to turn for information and support,\" said Meri-Margaret Deoudes, Chief Executive Officer of BCAN. \"As a rare form of urothelial cancer, UTUC has historically received limited attention despite the profound impact it can have on patients' lives. Establishing UTUC Awareness Day is an important step toward building greater recognition, creating a patient community, and encouraging more education, advocacy, and research focused on this disease.\"TYRA is currently dosing patients with dabogratinib, an investigational oral FGFR3-selective inhibitor, in a Phase 2 study called SURF303 (NCT07265947) for low-grade UTUC (LG-UTUC).\"At TYRA, we are committed to advancing new treatment approaches for patients living with urothelial cancers, particularly those facing limited therapeutic options and significant treatment burden,\" said Todd Harris, Ph.D., Chief Executive Officer of TYRA Biosciences. \"Dabogratinib is the only oral therapeutic candid...